Skip to content
Disclosery

Cormorant Asset Management, LP

Follow

13F filer, CIK 1583977, BOSTON, MA

Cormorant Asset Management, LP reported $1,951,406,063 across 50 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 59.19% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001583977-26-000007

Period
2026-06-30
Reported value
$1.95B
Holdings
50
Top 10 weight
59.19%
New
13
Sold out
10

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PBLSnew+4,615,612$126M
CLYMnew+2,106,000$27.5M
SYREnew+225,000$20M
DFTXnew+400,000$18.8M
ASNDnew+50,000$13.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PRAXreduced-245,500-$82.2M
CNTAexited-1,050,000-$41.7M
MBXreduced-570,000-$31.5M
EWTXreduced-750,000-$30.5M
MLTXreduced-1,275,000-$24.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001583977-26-000007, largest first. % of portfolio is the value over $1,951,406,063, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 870,000 shares; 2024Q4: 1,693,219 shares; 2025Q1: 1,745,000 shares; 2025Q2: 1,625,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 950,000 shares; 2026Q1: 885,500 shares; 2026Q2: 640,000 shares 640,000$214M10.98%-245,500Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 17,878,594 shares; 2025Q4: 17,878,594 shares; 2026Q1: 17,878,594 shares; 2026Q2: 17,878,594 shares 17,878,594$136M6.98%0Timeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 4,615,612 shares 4,615,612$126M6.47%newTimeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,940,921 shares; 2024Q4: 2,940,921 shares; 2025Q1: 2,940,921 shares; 2025Q2: 2,940,921 shares; 2025Q3: 3,192,521 shares; 2025Q4: 3,027,521 shares; 2026Q1: 2,957,521 shares; 2026Q2: 2,657,521 shares 2,657,521$111M5.67%-300,000Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,800,000 shares; 2026Q2: 6,000,000 shares 6,000,000$110M5.63%+200,000Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,406,534 shares; 2024Q4: 3,406,534 shares; 2025Q1: 4,101,992 shares; 2025Q2: 4,251,992 shares; 2025Q3: 4,010,000 shares; 2025Q4: 3,285,000 shares; 2026Q1: 3,260,000 shares; 2026Q2: 2,510,000 shares 2,510,000$102M5.23%-750,000Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,325,000 shares; 2024Q4: 8,325,000 shares; 2025Q1: 8,325,000 shares; 2025Q2: 8,325,000 shares; 2025Q3: 8,325,000 shares; 2025Q4: 8,265,000 shares; 2026Q1: 8,265,000 shares; 2026Q2: 7,000,000 shares 7,000,000$100M5.13%-1,265,000Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,147,396 shares; 2024Q4: 2,147,396 shares; 2025Q1: 2,147,396 shares; 2025Q2: 2,147,396 shares; 2025Q3: 2,147,396 shares; 2025Q4: 3,635,596 shares; 2026Q1: 3,949,241 shares; 2026Q2: 3,285,596 shares 3,285,596$92.5M4.74%-663,645Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,130,000 shares; 2024Q4: 2,130,000 shares; 2025Q1: 2,130,000 shares; 2025Q2: 2,130,000 shares; 2025Q3: 1,950,000 shares; 2025Q4: 1,350,000 shares; 2026Q1: 760,000 shares; 2026Q2: 675,000 shares 675,000$90M4.61%-85,000Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 950,000 shares; 2026Q2: 750,000 shares 750,000$73.1M3.75%-200,000Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 1,059,331 shares; 2025Q1: 1,059,331 shares; 2025Q2: 1,059,331 shares; 2025Q3: 1,059,331 shares; 2025Q4: 1,059,331 shares; 2026Q1: 1,059,331 shares; 2026Q2: 900,000 shares 900,000$63.2M3.24%-159,331Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,494,151 shares; 2024Q4: 8,494,151 shares; 2025Q1: 8,494,151 shares; 2025Q2: 8,494,151 shares; 2025Q3: 1,994,173 shares; 2025Q4: 4,355,433 shares; 2026Q1: 4,480,433 shares; 2026Q2: 3,205,433 shares 3,205,433$62.4M3.2%-1,275,000Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,629,529 shares; 2024Q4: 2,629,529 shares; 2025Q1: 2,629,529 shares; 2025Q2: 2,140,605 shares; 2025Q3: 2,140,605 shares; 2025Q4: 2,040,605 shares; 2026Q1: 2,890,605 shares; 2026Q2: 2,390,605 shares 2,390,605$58.6M3%-500,000Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 533,340 shares; 2025Q4: 533,340 shares; 2026Q1: 533,340 shares; 2026Q2: 533,340 shares 533,340$50.8M2.6%0Timeline
ANLADLAI NORTYE GROUP LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,897,857 shares; 2026Q2: 3,978,229 shares 3,978,229$45.7M2.34%+1,080,372Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,858,351 shares; 2024Q4: 1,600,000 shares; 2025Q1: 2,000,000 shares; 2025Q2: 1,600,000 shares; 2025Q3: 1,400,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 850,000 shares; 2026Q2: 550,000 shares 550,000$41M2.1%-300,000Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,425,000 shares; 2026Q2: 1,300,000 shares 1,300,000$40.6M2.08%-125,000Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 401,963 shares; 2024Q4: 55,539 shares; 2025Q1: 10,000 shares; 2025Q2: 10,000 shares; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 1,760,000 shares; 2026Q2: 2,610,000 shares 2,610,000$38.8M1.99%+850,000Timeline
AGMBAGOMAB THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,465,348 shares; 2026Q2: 2,465,348 shares 2,465,348$32M1.64%0Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 700,000 shares; 2024Q4: 700,000 shares; 2025Q1: 700,000 shares; 2025Q2: 700,000 shares; 2025Q3: 1,225,000 shares; 2025Q4: 1,120,000 shares; 2026Q1: 1,120,000 shares; 2026Q2: 550,000 shares 550,000$30.4M1.56%-570,000Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,106,000 shares 2,106,000$27.5M1.41%newTimeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,750,000 shares; 2026Q1: 3,900,000 shares; 2026Q2: 2,150,000 shares 2,150,000$26.9M1.38%-1,750,000Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,525,000 shares; 2026Q2: 1,000,000 shares 1,000,000$26M1.33%-525,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,466,460 shares; 2024Q4: 1,466,460 shares; 2025Q1: 1,466,460 shares; 2025Q2: 1,454,660 shares; 2025Q3: 1,363,200 shares; 2025Q4: 1,083,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 750,000 shares 750,000$25.9M1.33%-250,000Timeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,375,000 shares; 2024Q4: 2,375,000 shares; 2025Q1: 2,375,000 shares; 2025Q2: 2,375,000 shares; 2025Q3: 2,375,000 shares; 2025Q4: 2,344,971 shares; 2026Q1: 2,344,971 shares; 2026Q2: 2,344,971 shares 2,344,971$22M1.13%0Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 225,000 shares 225,000$20M1.02%newTimeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 400,000 shares 400,000$18.8M0.96%newTimeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,470,000 shares; 2024Q4: 3,250,000 shares; 2025Q1: 2,825,000 shares; 2025Q2: 2,175,000 shares; 2025Q3: 2,175,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 950,000 shares; 2026Q2: 500,000 shares 500,000$16.9M0.87%-450,000Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 750,000 shares; 2026Q2: 475,000 shares 475,000$16.8M0.86%-275,000Timeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 5,000,000 shares; 2025Q3: 5,000,000 shares; 2025Q4: 4,400,000 shares; 2026Q1: 5,500,000 shares; 2026Q2: 5,000,000 shares 5,000,000$15.6M0.8%-500,000Timeline
HLXCHELIX ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,297,500 shares; 2026Q2: 1,297,500 shares 1,297,500$13.8M0.71%0Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 50,000 shares 50,000$13.3M0.68%newTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 550,000 shares 550,000$12.1M0.62%newTimeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 500,000 shares; 2024Q4: 650,000 shares; 2025Q1: 525,000 shares; 2025Q2: 540,000 shares; 2025Q3: 430,000 shares; 2025Q4: 275,000 shares; 2026Q1: 190,000 shares; 2026Q2: 75,000 shares 75,000$8M0.41%-115,000Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 306,222 shares; 2026Q2: 1,028,242 shares 1,028,242$7.66M0.39%+722,020Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 250,000 shares; 2025Q1: 250,000 shares; 2025Q2: 200,000 shares; 2025Q3: 200,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 150,000 shares 150,000$7.61M0.39%newTimeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 500,000 shares; 2024Q4: 500,000 shares; 2025Q1: 400,000 shares; 2025Q2: 300,000 shares; 2025Q3: 300,000 shares; 2025Q4: 250,000 shares; 2026Q1: 225,000 shares; 2026Q2: 100,000 shares 100,000$6.29M0.32%-125,000Timeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,570,000 shares 3,570,000$6.25M0.32%newTimeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,100,000 shares; 2024Q4: 1,000,000 shares; 2025Q1: 600,000 shares; 2025Q2: 400,000 shares; 2025Q3: 400,000 shares; 2025Q4: 300,000 shares; 2026Q1: 250,000 shares; 2026Q2: 125,000 shares 125,000$4.68M0.24%-125,000Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,325,000 shares; 2024Q4: 1,825,000 shares; 2025Q1: 1,350,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 775,000 shares; 2025Q4: 500,000 shares; 2026Q1: 450,000 shares; 2026Q2: 175,000 shares 175,000$4.59M0.24%-275,000Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 100,000 shares; 2026Q2: 50,000 shares 50,000$4.08M0.21%-50,000Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 175,000 shares; 2026Q2: 75,000 shares 75,000$4.03M0.21%-100,000Timeline
RACCRESEARCH ALLIANCE CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 370,000 shares 370,000$3.96M0.2%newTimeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 225,000 shares; 2026Q1: 200,000 shares; 2026Q2: 100,000 shares 100,000$3.87M0.2%-100,000Timeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,250,000 shares 1,250,000$3.8M0.19%newTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 500,000 shares; 2025Q4: 400,000 shares; 2026Q1: 350,000 shares; 2026Q2: 200,000 shares 200,000$3.59M0.18%-150,000Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 175,000 shares 175,000$3.27M0.17%newTimeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,000,000 shares; 2024Q4: 425,000 shares; 2025Q1: 175,000 shares; 2025Q2: 175,000 shares; 2025Q3: 175,000 shares; 2025Q4: 125,000 shares; 2026Q1: 100,000 shares; 2026Q2: 50,000 shares 50,000$2.91M0.15%-50,000Timeline
BOLDBOUNDLESS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,000,000 shares 1,000,000$2.5M0.13%newTimeline
QNCXQUINCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 5,498 shares 5,498$100K0.01%newTimeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CNTACENTESSA PHARMACEUTICALS PLC1,050,000$41.7Mshares
MAZEMAZE THERAPEUTICS INC750,000$22.4Mshares
ASNDASCENDIS PHARMA A/S95,000$21.7Mshares
TERNTERNS PHARMACEUTICALS INC300,000$15.8Mshares
ZURAZURA BIO LTD1,450,000$8.63Mshares
AXSMAXSOME THERAPEUTICS INC.50,000$8.45Mshares
OLMAOLEMA PHARMACEUTICALS INC500,000$7.46Mcall
GLUEMONTE ROSA THERAPEUTICS INC400,000$6.58Mshares
RLYBRALLYBIO CORP400,000$3.59Mshares
CNTXCONTEXT THERAPEUTICS INC529,550$1.39Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001583977-26-000007 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001583977-26-000007 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001583977-26-000002 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001583977-26-000001 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001583977-25-000011 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001583977-25-000007 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001583977-25-000005 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001583977-25-000001 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001583977-24-000006 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001583977-24-000003 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001583977-24-000002 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001583977-24-000001 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001583977-23-000005 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001583977-23-000003 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001583977-23-000002 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001583977-23-000001 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0001583977-22-000007 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001583977-22-000006 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001583977-22-000002 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001583977-22-000001 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001583977-21-000009 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0001583977-21-000008 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0001583977-21-000005 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0001583977-21-000003 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-HR 0001583977-20-000005 Quarter ended 2020-09-302020-11-16acceptance time not in the bulk data set
13F-HR 0001583977-20-000004 Quarter ended 2020-06-302020-08-14acceptance time not in the bulk data set
13F-HR 0001583977-20-000003 Quarter ended 2020-03-312020-05-15acceptance time not in the bulk data set
13F-HR 0001583977-20-000001 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0001583977-19-000006 Quarter ended 2019-09-302019-11-14acceptance time not in the bulk data set
13F-HR 0001583977-19-000004 Quarter ended 2019-06-302019-08-14acceptance time not in the bulk data set
13F-HR 0001583977-19-000003 Quarter ended 2019-03-312019-05-15acceptance time not in the bulk data set
13F-HR 0001583977-19-000001 Quarter ended 2018-12-312019-02-14acceptance time not in the bulk data set
13F-HR 0001583977-18-000005 Quarter ended 2018-09-302018-11-14acceptance time not in the bulk data set
13F-HR 0001567619-18-000936 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR 0001583977-18-000004 Quarter ended 2018-03-312018-05-15acceptance time not in the bulk data set
13F-HR 0001583977-18-000002 Quarter ended 2017-12-312018-02-14acceptance time not in the bulk data set
13F-HR 0001583977-17-000005 Quarter ended 2017-09-302017-11-14acceptance time not in the bulk data set
13F-HR 0001583977-17-000004 Quarter ended 2017-06-302017-08-14acceptance time not in the bulk data set
13F-HR 0001583977-17-000003 Quarter ended 2017-03-312017-05-15acceptance time not in the bulk data set
13F-HR 0001583977-17-000002 Quarter ended 2016-12-312017-02-14acceptance time not in the bulk data set
13F-HR 0001583977-16-000008 Quarter ended 2016-09-302016-11-14acceptance time not in the bulk data set
13F-HR 0001140361-16-076682 Quarter ended 2016-06-302016-08-15acceptance time not in the bulk data set
13F-HR/A 0001140361-16-066002 Quarter ended 2016-03-312016-05-17acceptance time not in the bulk data set
13F-HR 0001140361-16-065689 Quarter ended 2016-03-312016-05-16acceptance time not in the bulk data set
13F-HR 0001140361-16-053224 Quarter ended 2015-12-312016-02-16acceptance time not in the bulk data set
13F-HR 0001140361-15-041700 Quarter ended 2015-09-302015-11-16acceptance time not in the bulk data set
13F-HR 0001140361-15-032295 Quarter ended 2015-06-302015-08-14acceptance time not in the bulk data set
13F-HR 0001140361-15-020350 Quarter ended 2015-03-312015-05-15acceptance time not in the bulk data set
13F-HR 0001140361-15-007391 Quarter ended 2014-12-312015-02-17acceptance time not in the bulk data set
13F-HR 0001140361-14-041889 Quarter ended 2014-09-302014-11-14acceptance time not in the bulk data set
13F-HR 0001140361-14-032474 Quarter ended 2014-06-302014-08-14acceptance time not in the bulk data set
13F-HR 0001140361-14-021247 Quarter ended 2014-03-312014-05-15acceptance time not in the bulk data set
13F-HR 0001140361-14-007278 Quarter ended 2013-12-312014-02-14acceptance time not in the bulk data set